GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Median PS Value

MiMedx Group (MiMedx Group) Median PS Value

: $7.96 (As of Today)
View and export this data going back to 2008. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. MiMedx Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.607. MiMedx Group's 10-Year median PS Ratio is 3.0533. Therefore, the Median PS Value for today is $7.96.

As of today (2024-04-18), MiMedx Group's share price is $6.16. MiMedx Group's Median PS Value is $7.96. Therefore, MiMedx Group's Price to Median PS Value for today is 0.77.

The historical rank and industry rank for MiMedx Group's Median PS Value or its related term are showing as below:

MDXG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27   Med: 0.53   Max: 1.1
Current: 0.77

During the past 13 years, the highest Price to Median PS Value of MiMedx Group was 1.10. The lowest was 0.27. And the median was 0.53.

MDXG's Price-to-Median-PS-Value is ranked worse than
59.3% of 258 companies
in the Biotechnology industry
Industry Median: 0.655 vs MDXG: 0.77

MiMedx Group Median PS Value Historical Data

The historical data trend for MiMedx Group's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.72 15.18 11.42 10.39 7.96

MiMedx Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.39 10.50 10.41 9.90 7.96

Competitive Comparison

For the Biotechnology subindustry, MiMedx Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group Price-to-Median-PS-Value Distribution

For the Biotechnology industry and Healthcare sector, MiMedx Group's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Price-to-Median-PS-Value falls into.



MiMedx Group Median PS Value Calculation

MiMedx Group's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=2.607*3.0533
=7.96

10-Year Median PS Ratio is 3.0533.
MiMedx Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.607.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiMedx Group  (NAS:MDXG) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

MiMedx Group's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=6.16/7.96
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiMedx Group Median PS Value Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604